PAGOSA SPRINGS, Colo.--(BUSINESS WIRE)--July 14, 2006--NZyme Pharmaceuticals, Inc. (d/b/a NZyme Pharm) announced today that they have a patent pending application for NZyme brand (Subtilisin NAT) for decreasing whole blood viscosity in the central therapeutic role of preventing and treating vascular disease such as heart attacks and ischemic strokes, essential hypertension and deep vein thrombosis.
